菜单

WuXia™ Cell Line Development Service

Stable Cell Lines with Fast IND Filing and Seamless Global Scale

WuXi Biologics’ cell line development services establish the foundation for successful biologics manufacturing, grounding every molecule in stability, scalability, and compliance. From DNA sequence to master cell bank (MCB) creation, our integrated approach accelerates programs while safeguarding quality and reproducibility.

Set your biologic up for every subsequent success.

Download the Service Sheet
Explore Cell Culture Media

CRDMO Service across a Full Spectrum of Modalities

Monoclonal Antibody
Bispecific Antibody
Fc-fusion Protein
Antibody-Drug Conjugate
Viral Vaccine
Oncolytic Virus
Virus-Like Particle
Recombinant Protein
Antibody Fragment

Whether you are developing a standard monoclonal antibody (mAb) or a more complex mammalian-expressed modality, WuXi Biologics brings the precision, throughput, and expertise to accelerate progress. Performance extends to difficult-to-express biologics, reflected in average titers of ≥ 5.1 g/L achieved across more than 220 bispecific antibody (BsAb) programs.

WuXia™ Technology Platforms for CHO and HEK293 Cell Lines

WuXia technology platforms deliver stable, highyield CHO-K1 and HEK293 clones that support scalability and manufacturability from the outset. Targeted integration and other specialized capabilities unique to each platform align cell line development with individual program needs. Notably, WuXia RidGS, WuXiaADCC PLUS™, and WuXia293Stable grant control over desired post-translational modifications (PTMs), supporting product consistency and manufacturability.

Platform standardization underpins this flexibility. Accepted by regulatory agencies worldwide, WuXia harmonizes cell line development workflows and manufacturing requirements. Compatibility with automated, high-throughput clone screening further lowers manual intervention and program risk.

Key Specifications

Targeted Integration

Antibiotic-Free Selection

Antibiotic Selection

DNA to MCB 9 to 10 weeks 9 to 10 weeks 9 to 10 weeks
Average mAb titer 8 g / L 7.4 g / L 6 g / L
Quality Consistent pool-to-clone product quality 10 to 50% reduction in Mannose-5 levels Zero sequence variants at
the genetic level
Stability 99% clone stability after population doubling level (PDL) 60 90% clone stability after 60 PDLs 90% clone stability after 60 PDLs

Performance highlights across the main WuXia technology platforms

Speed, Precision, and Productivity by Design

WuXia TrueSite employs targeted integration to power faster, more precise, more productive cell line development:

  • Accelerate CMC timelines, reaching IND-enabling milestones in 6 months or less.
  • Achieve consistent productivity and product quality from mAb pool to clone, with high clone stability.
  • Scale seamlessly from Ambr 15 to 200 L with high model consistency.

WuXia TrueSite uses recombinase-mediated cassette exchange (RMCE) to place the gene of interest (GOI) into predefined genomic landing pad (LP). Targeted integration ensures consistent gene location and expression, minimizing clone-to-clone variability, rework, and development timelines to move programs efficiently into clinical development.

Antibiotic-Free Cell Selection

WuXia RidGS enables antibiotic-free cell line development for general biologics programs requiring long-term stability and wellcontrolled N-glycan profiles. Although antibiotic cell selection offers speed and broad vector compatibility, certain regulatory requirements, extended manufacturing campaigns, and commercial-scale programs benefit from non-antibiotic cell selection.

WuXia RidGS uses zinc-finger nuclease–mediated knockout of the endogenous glutamine synthetase (GS) gene in CHO cells. Only cells that integrate both the therapeutic gene and an exogenous GS gene survive, creating a uniform and stable population early in development. This approach provides consistent expression and improved glycosylation profiles, including reduced high-mannose glycoforms.

Foundational Cell Line Development

The WuXia CHO-K1 technology platform forms the proprietary foundation for WuXi Biologics’ cell line development services. Thoroughly tested and widely used, WuXia CHO-K1 broadly supports general biologics applications, including mAb, BsAb, fusion protein, and recombinant protein modalities.

WuXi Biologics deploys WuXia CHO-K1 as a standalone technology platform or pairs it with WuXia RidGS, WuXiaADCC Plus, or WuXia293Stable. The pairings address key development challenges such as antibiotic-free manufacturing, antibody potency, and complex protein expression.

10.8 g/L Maximum mAb titer
> 98% Lead clone stability
> 1,200 Cell lines development
6 Commercial products approved

Afucosylated Antibodies for Greater Immune Potency

The WuXiaADCC PLUS technology platform incorporates a fucosyltransferase 8 knockout to consistently produce afucosylated antibodies. Afucosylation removes core fucose from Fc glycans, strengthening antibody binding to immune cell receptors and enhancing antibody-dependent cellular cytotoxicity (ADCC).

The platform simultaneously increases immune-cell-mediated killing and maintains robust expression, stability, and manufacturability. Supporting clinical and commercial production of effector-function–driven antibodies, regulatory agencies, including FDA and EMA, widely recognize WuXiaADCC PLUS as a validated strategy for improving ADCC potency.

Express the Difficult-to-Express

WuXia293Stable uses HEK293 cells adapted to serum-free suspension culture to improve expression of biologics that are structurally or functionally challenging to CHO systems.

With titers up to 5 g/L and human-like PTMs, WuXia293Stable offers long-term expression stability and scales to 1,000 L perfusion or 2,000 L fed-batch manufacturing. By mitigating truncation, misfolding, and poor expression, optimized WuXia293Stable clones increase yield for difficult-to-express proteins by at least 7.6-fold with consistent results across multiple molecule types.

Integrated, Expedited Cell Line Development Workflow

As a single accountable CRDMO, WuXi Biologics integrates cell line development with process development, analytical validation, and manufacturing. This model supports reliable IND readiness with consistent global quality.

We offer multiple cell line development workflows. All options accelerate 30-PDL cell line stability assessment to attain 4.5-, 4-, or 2.5-month cell line development. Timelines depend on program needs and cell banking strategy: parental cell bank (PCB) or research cell bank (RCB).

Advanced analytics, biosafety testing, and automated data oversight through a custom laboratory data management system ensure traceability and integrity at every stage.

Read the White Paper
Download the Scientific Poster

Flexible CMC Service Configurations Backed by Expert Guidance

In addition to mammalian cell line development, WuXi Biologics offers microbial strain development, expanding the scope of supported biologic modalities. Services are available as fully integrated or standalone offerings, aligning with client timelines for IND and BLA submissions.

Set Your Biologic Up for Long-Term Success

From clone selection to commercial production, WuXi Biologics accelerates biologics
programs with industry-leading performance, quality, and compliance.

Contact Us Today